Evidence map›Paper›PMID 32752175›Full record

ReviewNutrients2020

Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases.

Moschoula Passali, Knud Josefsen, Jette Lautrup Frederiksen, Julie Christine Antvorskov

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. The Effects of Gluten on Weight Gain, Hematological, Biochemical, and Various Endocrinological Parameters.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Moschoula PassaliMultiple Sclerosis Clinic, Department of Neurology, Rigshospitalet-Glostrup, Valdemar Hansens Vej 13, 2600 Glostrup, Denmark.
Knud JosefsenThe Bartholin Institute, Rigshospitalet, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark.
Jette Lautrup FrederiksenMultiple Sclerosis Clinic, Department of Neurology, Rigshospitalet-Glostrup, Valdemar Hansens Vej 13, 2600 Glostrup, Denmark.ORCID 0000-0003-1661-7438
Julie Christine AntvorskovThe Bartholin Institute, Rigshospitalet, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark.
Rigshospitalet · DKUniversity of Copenhagen · DK

Funding

Kirsten og Freddy Johansens Fond NAScleroseforeningen A38270
6 · The paper itself

Abstract

In this review, we summarize the clinical data addressing a potential role for gluten in multiple sclerosis (MS), psoriasis, type 1 diabetes (T1D) and autoimmune thyroid diseases (ATDs). Furthermore, data on the prevalence of celiac disease (CD) and gluten-related antibodies in the above patient groups are presented. Adequately powered and properly controlled intervention trials investigating the effects of a gluten-free diet (GFD) in non-celiac patients with MS, psoriasis, T1D or ATDs are lacking. Only one clinical trial has studied the effects of a GFD among patients with MS. The trial found significant results, but it is subject to major methodological limitations. A few publications have found beneficial effects of a GFD in a subgroup of patients with psoriasis that were seropositive for anti-gliadin or deamidated gliadin antibodies, but no effects were seen among seronegative patients. Studies on the role of gluten in T1D are contradictive, however, it seems likely that a GFD may contribute to normalizing metabolic control without affecting levels of islet autoantibodies. Lastly, the effects of a GFD in non-celiac patients with ATDs have not been studied yet, but some publications report that thyroid-related antibodies respond to a GFD in patients with concomitant CD and ATDs. Overall, there is currently not enough evidence to recommend a GFD to non-celiac patients with MS, psoriasis, ATDs or T1D.

Indexed as

AutoantibodiesAutoimmunityCeliac DiseaseComorbidityDiabetes Mellitus, Type 1Diet, Gluten-FreeGliadinGlutensHashimoto DiseaseHumansMultiple SclerosisPrevalencePsoriasisAutoantibodiesGliadinGlutensautoimmune thyroid diseaseautoimmunityceliac diseasegliadinglutengluten-free dietmultiple sclerosisneurologypsoriasistype 1 diabetes

Identifiers

PMID32752175
PMCPMC7468712
OpenAlexW3046408341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.